Who We Are
As the world's leading provider of generic drugs, Teva Pharmaceuticals understands the importance of making safe, quality medications accessible —and affordable.
At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future. With the acquisition of Actavis Generics in 2016, our company now offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale.
One in ten of the 3.66 billion generic prescriptions written in the United States is filled with a Teva product.1 In 2018, generics saved the healthcare system in the United States $293 billion, and Teva was responsible for $42 billion of these savings.2
Teva manufactures more than 500 generic prescription and over-the-counter products in more than 2,000 dosage strengths and package sizes, including oral solid dosage forms, injectable products, inhaled products, liquids, ointments and creams.2 Additionally, Teva employs nearly 6,800 employees in the United States and owns or leases approximately 20 manufacturing and R&D facilities in North America.2,3
Teva Pharmaceuticals USA is a wholly owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the world's leading pharmaceutical companies.
Learn more about our history and how we have grown to be the leading provider of generic drugs.
Choosing Teva Generics is choosing to enjoy the benefits only Teva can provide. Learn more about our advantages.
1. Internal Data on File. IQVIA NPA Data (as of MAT December 2019).
2. Teva Global Economic Impact Report. January 2020.
3. Teva Pharmaceutical Industries Limited Form 10-K for the fiscal year ended December 31, 2018.